Paper32101775
A network pharmacology approach to investigating the mechanism of Tanshinone IIA for the treatment of liver fibrosis.
Shi MJ and 5 others. J Ethnopharmacol, 2020. Cited by 48 papers, by iCite.
Cite this record
ConductScience Library. A network pharmacology approach to investigating the mechanism of Tanshinone IIA for the treatment of liver fibrosis. Papers, record 32101775. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32101775
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- A network pharmacology approach to investigating the mechanism of Tanshinone IIA for the treatment of liver fibrosis.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Abietanes | Major topic |
| Liver | Major topic |
| Liver Cirrhosis | Major topic |
| Animals | |
| Carbon Tetrachloride | |
| Cell Line | |
| Cell Proliferation | |
| Hepatic Stellate Cells | |
| Humans | |
| Male | |
| Protein Interaction Maps | |
| Rats, Wistar |
Source PubMed
Cited by34
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 48 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42488836 | Systems pharmacology of traditional Chinese medicine in fibrosis: From multi-target mechanisms to translational validation. | Chin Herb Med | 2026 | https://conductscience.org/library/papers/42488836 | PubMed |
| 41322110 | The Role of Macrophage Polarization and Ferroptosis in the Progression of Liver Fibrosis. | Can J Gastroenterol Hepatol | 2025 | https://conductscience.org/library/papers/41322110 | PubMed |
| 40666178 | Tanshinone IIA alleviates liver fibrosis by suppressing hepatic stellate cell proliferation via ERK/cyclin D1/p-Smad3L signaling axis. | Iran J Basic Med Sci | 2025 | https://conductscience.org/library/papers/40666178 | PubMed |
| 40148411 | Accelerators of chronic hepatitis B fibrosis cirrhosis CCND1 gene expression and promoter hypomethylation. | Sci Rep | 2025 | https://conductscience.org/library/papers/40148411 | PubMed |
| 39869574 | Mechanism of Radix Bupleuri and Hedysarum Multijugum Maxim drug pairs on liver fibrosis based on network pharmacology, bioinformatics and molecular dynamics simulation. | PLoS One | 2025 | https://conductscience.org/library/papers/39869574 | PubMed |
| 39606260 | Exploration of compatibility rules and discovery of active ingredients in TCM formulas by network pharmacology. | Chin Herb Med | 2024 | https://conductscience.org/library/papers/39606260 | PubMed |
| 39468572 | The role of Chinese herbal medicine in the regulation of oxidative stress in treating hypertension: from therapeutics to mechanisms. | Chin Med | 2024 | https://conductscience.org/library/papers/39468572 | PubMed |
| 38689349 | Blockade of PI3K/AKT signaling pathway by Astragaloside IV attenuates ulcerative colitis via improving the intestinal epithelial barrier. | J Transl Med | 2024 | https://conductscience.org/library/papers/38689349 | PubMed |
| 38675723 | Anti-Tumor Activity and Mechanism of Silibinin Based on Network Pharmacology and Experimental Verification. | Molecules | 2024 | https://conductscience.org/library/papers/38675723 | PubMed |
| 38590313 | The role of PI3k/AKT signaling pathway in attenuating liver fibrosis: a comprehensive review. | Front Med (Lausanne) | 2024 | https://conductscience.org/library/papers/38590313 | PubMed |
| 37878048 | Molecular mechanism of quercetin in treating RA-ILD based on network pharmacology, molecular docking, and experimental validation. | Naunyn Schmiedebergs Arch Pharmacol | 2024 | https://conductscience.org/library/papers/37878048 | PubMed |
| 37444525 | A Review of Herbal Resources Inducing Anti-Liver Metastasis Effects in Gastrointestinal Tumors via Modulation of Tumor Microenvironments in Animal Models. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37444525 | PubMed |
| 36984421 | Pharmacology-Based Prediction of the Targets and Mechanisms for Icariin against Myocardial Infarction. | Medicina (Kaunas) | 2023 | https://conductscience.org/library/papers/36984421 | PubMed |
| 36845955 | Salviae miltiorrhiza against human lung cancer: A review of its mechanism (Review). | Exp Ther Med | 2023 | https://conductscience.org/library/papers/36845955 | PubMed |
| 36838918 | Confusoside from Anneslea fragrans Alleviates Acetaminophen-Induced Liver Injury in HepG2 via PI3K-CASP3 Signaling Pathway. | Molecules | 2023 | https://conductscience.org/library/papers/36838918 | PubMed |
| 36627345 | Salvianolic acid B suppresses hepatic fibrosis by inhibiting ceramide glucosyltransferase in hepatic stellate cells. | Acta Pharmacol Sin | 2023 | https://conductscience.org/library/papers/36627345 | PubMed |
| 36313326 | Tandem mass tag-based proteomics analysis reveals the multitarget mechanisms of Phyllanthus emblica against liver fibrosis. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/36313326 | PubMed |
| 36204239 | Salvia miltiorrhiza in thorax and abdomainal organ fibrosis: A review of its pharmacology. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/36204239 | PubMed |
| 36091584 | Tanshinone IIA Ameliorates Nonalcoholic Steatohepatitis in Mice by Modulating Neutrophil Extracellular Traps and Hepatocyte Apoptosis. | Evid Based Complement Alternat Med | 2022 | https://conductscience.org/library/papers/36091584 | PubMed |
| 36081936 | Traditional Chinese medicine: An important source for discovering candidate agents against hepatic fibrosis. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/36081936 | PubMed |
Genes9
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ACTA1 | 58 | PubTator's text mining | https://conductscience.org/library/genes/58 | NCBI Gene |
| AKT1 | 207 | PubTator's text mining | https://conductscience.org/library/genes/207 | NCBI Gene |
| CCND1 | 595 | PubTator's text mining | https://conductscience.org/library/genes/595 | NCBI Gene |
| COL1A2 | 1278 | PubTator's text mining | https://conductscience.org/library/genes/1278 | NCBI Gene |
| JUN | 3725 | PubTator's text mining | https://conductscience.org/library/genes/3725 | NCBI Gene |
| MAPK14 | 1432 | PubTator's text mining | https://conductscience.org/library/genes/1432 | NCBI Gene |
| MMP9 | 4318 | PubTator's text mining | https://conductscience.org/library/genes/4318 | NCBI Gene |
| MYC | 4609 | PubTator's text mining | https://conductscience.org/library/genes/4609 | NCBI Gene |
| RELA | 5970 | PubTator's text mining | https://conductscience.org/library/genes/5970 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32101775
GET https://conductscience.org/api/papers/v1/32101775/cited_by?page=2